Can-Fite BioPharma Reports Positive Clinical Data in Pancreatic Cancer and Liver Cancer, Expands IP Portfolio and Advances Metabolic Disease Pipeline.
ByAinvest
Thursday, Mar 26, 2026 9:28 am ET1min read
CANF--
Can-Fite BioPharma reported 2025 financial results and clinical progress, highlighting positive data in Phase 2a pancreatic cancer and 9 years of cancer-free survival in a liver cancer patient. The company also observed complete resolution of esophageal varices in a patient with decompensated cirrhosis and expanded Namodenoson's therapeutic potential into metabolic diseases. Can-Fite strengthened its intellectual property portfolio with multiple patent allowances across key territories.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue



Comments
No comments yet